ALZN Stock Forecast: Alzamend Neuro, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.76
−25.48% on the day

The median 12-month analyst price target for Alzamend Neuro, Inc. is $26. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$3.7M
Ticker Nerd rank
27/ 100
Median analyst target
$26
Analysts covering
1
Revenue$0.0
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$1.1M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−38.7%
1M
−41.5%
YTD
−58.2%
1Y
−61.4%
From 52W high
−68.7%
From 52W low
0.0%
$0.76
$2.43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Alzamend Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
27/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
56
Revisions
48
Volatility
39
Momentum
37
Quality
34
Issuance
24
Growth
23
Value
13

Accruals (56): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (13): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALZN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALZN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26ALZNHigh $26Median $26Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$26
Low
$26
Median
$26
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026Ascendiant CapitalMaintainsBuy$25 → $26
22 Dec 2025Ascendiant CapitalMaintainsBuy$42 → $28
25 Sept 2025Ascendiant CapitalMaintainsBuy—
21 Aug 2025Ascendiant CapitalMaintainsBuy—
17 Mar 2025Ascendiant CapitalMaintainsBuy—
16 Dec 2024Ascendiant CapitalMaintainsBuy—
11 Nov 2024Ascendiant CapitalMaintainsBuy—
12 Apr 2023Maxim GroupInitiatesBuy$1.50
1 Oct 2021Ascendiant CapitalInitiatesBuy$8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALZN.

Market Radar

This page is one stock. Monday covers all of them.

ALZN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALZN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Alzamend Neuro, Inc. returned −61.4% against +6.9% for the S&P 500, dividends included.

ALZN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ALZNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALZN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−163.2%

Higher than 9% of US stocks

Return on assets
−76.4%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alzamend Neuro, Inc. has a market value of $3.7M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$9.1M.

  • Free cash flow in the twelve months to 31 July 2026: −$6.8M.

  • Shares outstanding: 4.8M.

  • Alzamend Neuro, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

ALZN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALZNAlzamend Neuro, Inc.$3.7M27
SILOSilo Pharma, Inc.$3.6M16
LTRNLantern Pharma, Inc.$3.9M24
IMNNImunon, Inc.$3.5M12
CRISCuris, Inc.$4.1M35
LIMNLiminatus Pharma, Inc.$3.4M10
XBIOXenetic Biosciences, Inc.$3.3M28

Take a look at ALZN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Alzamend Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ALZN

What is the ALZN stock price forecast for 2026-2027?

The median 12-month analyst price target for Alzamend Neuro, Inc. is $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALZN stock a buy right now?

Of the 1 analyst covering Alzamend Neuro, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alzamend Neuro, Inc. 27 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALZN?

As at 21 Nov 2026, Alzamend Neuro, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (56 of 100).

Will ALZN stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $26, and Ticker Nerd's factor model ranks Alzamend Neuro, Inc. 27 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALZN stock forecast for 2030?

No analyst covering Alzamend Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.

How has ALZN stock performed over the past year?

Alzamend Neuro, Inc. returned -61.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alzamend Neuro, Inc. do?

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease.

Company

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease. The company is working across major therapeutic areas including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its research and development activities are directed toward advancing novel product candidates intended to address conditions with significant unmet medical need in neuroscience and mental health. Headquartered in Atlanta, Georgia, Alzamend Neuro plays a specialized role in the biotech market as a developer of investigational therapies focused on the central nervous system and immune-based approaches to Alzheimer’s disease.

CEO Mr. Stephan Jackman · 4 employees · United States · https://www.alzamend.com